Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • No direct link found between rising inequality, reduced trust

  • Diversity in developmental trajectories in kids with autism spectrum disorder

  • Common elements of STEM schools identified

  • Financial incentives help pregnant women to quit smoking

  • Grant to develop therapy to protect against nerve agents

  • Up to 2 per cent of Germany's population is dependent on hypnotics

  • Low-frequency deep brain stimulation improves difficult-to-treat Parkinson's symptoms

  • Sexual offending treatment programs in prisons, hospitals are ineffective

  • Fluorescent dyes 'light up' brain cancer cells

  • Stress shared by same-sex couples can have unique health impacts

  •